Polychronis Pavlidis1, Azhar Ansari, John Duley, Iulia Oancea, Timothy Florin. 1. *Department for Digestive Diseases, Surrey and Sussex Healthcare NHS Trust, East Surrey Hospital, Redhill, United Kingdom; †Mater Research Institute, University of Queensland, Woolloongabba, Australia; ‡Mater Pathology Service, South Brisbane, Australia; and §Department of Gastroenterology, Mater Health Services, South Brisbane, Australia.
Abstract
BACKGROUND: Thioguanine (TG) is a treatment for inflammatory bowel disease, but association with nodular regenerative hyperplasia has restricted its use. We conjectured that splitting a therapeutic daily dose of TG would be efficacious and should avoid liver toxicity. METHODS: We report on 62 patients with severe inflammatory bowel disease not responding to prednisolone, conventional thiopurines, biologics, or calcineurin inhibitors. Patients were prescribed oral split-daily TG to avoid individual doses >0.3 mg/kg. Data on concomitant medication, clinical efficacy measured by Harvey-Bradshaw Index for Crohn's, or Simple Clinical Colitis Score for ulcerative/indeterminate colitis (UC), and some paired endoscopies were available. Safety was followed clinically and with bloods at 2 centers. All patients at the U.K. center had a liver biopsy or magnetic resonance imaging after 6 months. Twenty-one patients had serial ultrasounds at the Australian center. RESULTS: At 6 months, 19/21 of patients with Crohn's disease and 27/38 with ulcerative colitis had improved clinical activity. At study end, 53% of patients maintained improved clinical activity of steroids. Median duration of TG was 8 (0.3-45) months, median dose was 0.6 (0.3-1) mg/kg per day. Previous thiopurine-related adverse reactions were not encountered. Twenty-nine patients withdrew because of loss to follow-up, medical adverse events, or surgery. Possible early nodular regenerative hyperplasia was found on liver biopsy in 1 patient who was heterozygote deficient for thiopurine methyltransferase; the TG dose was lowered. TG was discontinued in a patient with nodular regenerative hyperplasia and concomitant antiphospholipid syndrome. There was 1 successful term pregnancy; cord blood and breast milk TG were low. CONCLUSIONS: Split-dose TG seemed well tolerated and efficacious in this retrospective study of patients with difficult inflammatory bowel disease.
BACKGROUND:Thioguanine (TG) is a treatment for inflammatory bowel disease, but association with nodular regenerative hyperplasia has restricted its use. We conjectured that splitting a therapeutic daily dose of TG would be efficacious and should avoid liver toxicity. METHODS: We report on 62 patients with severe inflammatory bowel disease not responding to prednisolone, conventional thiopurines, biologics, or calcineurin inhibitors. Patients were prescribed oral split-daily TG to avoid individual doses >0.3 mg/kg. Data on concomitant medication, clinical efficacy measured by Harvey-Bradshaw Index for Crohn's, or Simple Clinical Colitis Score for ulcerative/indeterminate colitis (UC), and some paired endoscopies were available. Safety was followed clinically and with bloods at 2 centers. All patients at the U.K. center had a liver biopsy or magnetic resonance imaging after 6 months. Twenty-one patients had serial ultrasounds at the Australian center. RESULTS: At 6 months, 19/21 of patients with Crohn's disease and 27/38 with ulcerative colitis had improved clinical activity. At study end, 53% of patients maintained improved clinical activity of steroids. Median duration of TG was 8 (0.3-45) months, median dose was 0.6 (0.3-1) mg/kg per day. Previous thiopurine-related adverse reactions were not encountered. Twenty-nine patients withdrew because of loss to follow-up, medical adverse events, or surgery. Possible early nodular regenerative hyperplasia was found on liver biopsy in 1 patient who was heterozygote deficient for thiopurine methyltransferase; the TG dose was lowered. TG was discontinued in a patient with nodular regenerative hyperplasia and concomitant antiphospholipid syndrome. There was 1 successful term pregnancy; cord blood and breast milk TG were low. CONCLUSIONS: Split-dose TG seemed well tolerated and efficacious in this retrospective study of patients with difficult inflammatory bowel disease.
Authors: Mark G Ward; Kamal V Patel; Viraj C Kariyawasam; Rishi Goel; Ben Warner; Tim R Elliott; Paul A Blaker; Peter M Irving; Anthony M Marinaki; Jeremy D Sanderson Journal: United European Gastroenterol J Date: 2016-08-01 Impact factor: 4.623
Authors: I Oancea; R Movva; I Das; D Aguirre de Cárcer; V Schreiber; Y Yang; A Purdon; B Harrington; M Proctor; R Wang; Y Sheng; M Lobb; R Lourie; P Ó Cuív; J A Duley; J Begun; T H J Florin Journal: Gut Date: 2016-07-13 Impact factor: 23.059
Authors: Melek Simsek; Debbie S Deben; Carmen S Horjus; Melanie V Bénard; Birgit I Lissenberg-Witte; Hans J C Buiter; Matthijs van Luin; Margien L Seinen; Chris J J Mulder; Dennis R Wong; Nanne K H de Boer; Adriaan A van Bodegraven Journal: Aliment Pharmacol Ther Date: 2019-05-16 Impact factor: 8.171
Authors: Ahmed B Bayoumy; Elsa L S A van Liere; Melek Simsek; Ben Warner; Aathavan Loganayagam; Jeremy D Sanderson; Simon Anderson; Jonathan Nolan; Nanne K de Boer; Chris J J Mulder; Azhar Ansari Journal: BMC Gastroenterol Date: 2020-09-11 Impact factor: 3.067